Abstract
This study evaluated the Cutaneous Lupus Erythematosus (CLE) Quality of Life index (CLEQoL) as a valid, accurate, and longitudinally responsive patient reported outcome measure amongst CLE patients. Results show that the CLEQoL accurately captures QoL impacts amongst CLE patients and tracks changes in QoL impacts across time and disease activity.